- Market Capitalization, $K 14,796,076
- Shares Outstanding, K 687,550
- Annual Sales, $ 5,299 M
- Annual Income, $ 704,630 K
- 60-Month Beta 1.08
- Price/Sales 2.78
- Price/Cash Flow 13.70
- Price/Book 2.50
|Period||Period Low||Period High||Performance|
| || |
+1.04 (+5.11%)since 10/11/19
| || |
-0.63 (-2.86%)since 08/09/19
| || |
+0.21 (+0.99%)since 11/09/18
Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, has now introduced AlphaID(TM), a...
- ART enables greater workflow efficiency and lean sample management, supporting laboratories' path towards total automation
The Grifols Clinical Research team, led by Dr. Antonio Páez, today presented additional results of its AMBAR (Alzheimer Management by Albumin Replacement) clinical trial for the treatment of Alzheimer's...
Companies In The News Are: OASM,GOL,GRFS,DELL
Grifols (MCE:GRF) (MCE:GRF.P) (NASDAQ: GRFS), a leading global producer of plasma-derived medicines, announced today that Xembify®, its new 20% subcutaneous immunoglobulin, has been approved by the U.S....
Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced it has been selected by Soludia Maghreb,...
GRFS vs. ORINY: Which Stock Is the Better Value Option?
Grifols is pleased to announce the opening of a new Biotest plasma donor center located at 108 West Hendry Street, Hinesville, Georgia. The 11,000 square foot state-of-the-art facility officially opened...
Grifols, one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that its long-term global initiative to providing treatment to people with...
Transparency Market Research (TMR) points entry of new players in the global immunoglobulins market. This is due to a significant boost in number of FDA approvals for immunoglobulins drugs and vaccinations....
|Biotech Vaneck ETF|
|Nasdaq Biotechnology Ishares ETF|
|Bldrs Europe Select ADR Index Fund Invesco|
|Bldrs Developed Markets 100 ADR Index Fund Inves|
|SPDR Kensho & New Economies Composite ETF|